List of Excipients in Branded Drug EVKEEZA

« Back to Dashboard

EVKEEZA Excipient Strategy and Commercial Opportunities in Evinacumab Formulation

Last updated: August 18, 2026

EVKEEZA (evinacumab-dgnb) is an intravenously administered monoclonal antibody for homozygous familial hypercholesterolemia (HoFH). Its commercial formulation uses a conventional low-complexity excipient system: histidine buffer, L-arginine hydrochloride, polysorbate 80, and water for injection. The largest opportunities are not likely to come from replacing the core excipients. They are in reducing infusion burden, improving vial utilization, extending shelf life, supporting global supply, and developing differentiated presentations that remain compatible with biologic stability and regulatory requirements.

What is EVKEEZA and how is it administered?

EVKEEZA contains evinacumab, a fully human monoclonal antibody that inhibits angiopoietin-like protein 3, or ANGPTL3. It is approved for patients aged 5 years and older with HoFH as an adjunct to other lipid-lowering treatments.

Attribute	EVKEEZA status
Active ingredient	Evinacumab-dgnb
Drug class	Fully human monoclonal antibody
Target	ANGPTL3
FDA approval	February 11, 2021
Indication	Adjunct treatment for HoFH
Route	Intravenous infusion
Dose	15 mg/kg once every four weeks
Presentations	345 mg/2.3 mL and 1,200 mg/8 mL single-dose vials
Concentration	150 mg/mL
Primary commercial sponsor	Regeneron Pharmaceuticals
Ex-US commercial rights	Ultragenyx Pharmaceutical in applicable territories
Reference-product exclusivity	Expected to extend to February 2033 under the FDA biologics framework, subject to the Purple Book record

The recommended dose requires an infusion over approximately 60 minutes. Patients generally receive 13 administrations per year. The weight-based dose creates a recurring vial-selection and drug-wastage issue, particularly for pediatric and lower-weight patients. [1]

What excipients are used in EVKEEZA?

The U.S. prescribing information identifies histidine, L-arginine hydrochloride, polysorbate 80, and water for injection as inactive ingredients. The formulation has a pH of approximately 6.0 and is supplied as a sterile, preservative-free solution. [1]

Excipient	Formulation role	Commercial relevance
Histidine	Buffering agent and pH control	Supports protein stability during storage
L-Arginine hydrochloride	Stabilizer and aggregation-control excipient	Helps manage protein-protein interactions and solution behavior
Polysorbate 80	Surfactant	Reduces interface-induced aggregation and adsorption
Water for injection	Solvent	Parenteral vehicle

The formulation is consistent with established monoclonal-antibody practice. Histidine is widely used in biologics because it provides buffering near mildly acidic pH values. Arginine can reduce self-association and aggregation, while polysorbate 80 limits damage caused by air-liquid, liquid-solid, and container interfaces.

The excipient system is commercially practical because it relies on globally available pharmaceutical-grade materials rather than a proprietary stabilizer with limited supply capacity. Its main constraints are typical of injectable antibodies: polysorbate degradation, particulate control, container compatibility, freeze-thaw sensitivity, and control of subvisible particles.

How strong is the EVKEEZA formulation from an excipient perspective?

The current formulation is technically defensible but not highly differentiated. Its strength is operational reliability, not formulation complexity.

Stability profile

A histidine-arginine-polysorbate system can support long-term refrigerated storage while maintaining antibody monomer content and biological activity. The main degradation pathways are likely to include:

• Chemical modification of the antibody, including oxidation and deamidation.
• Physical aggregation during storage or agitation.
• Polysorbate hydrolysis and oxidation.
• Interactions with vial, stopper, syringe, or infusion-system surfaces.
• Formation of visible or subvisible particles.

For a product administered every four weeks, stability is commercially important. A longer shelf life reduces inventory write-offs and improves distribution to specialty centers. Stability at controlled room temperature, even for limited periods, would also improve pharmacy handling and reduce cold-chain exposure.

Polysorbate risk

Polysorbate 80 is widely accepted but has known degradation risks. Hydrolysis can generate free fatty acids, which may contribute to particle formation. Oxidation can produce reactive species that affect the antibody. These risks become more important as products move toward higher concentrations, longer storage, smaller-volume delivery, or prefilled systems.

A supplier strategy should include:

1. Tight control of peroxide and related impurity levels.
2. Lot-to-lot monitoring of fatty-acid composition.
3. Defined controls for hydrolysis and oxidation.
4. Compatibility testing with vial components and infusion materials.
5. A qualified secondary source.

Polysorbate 20, poloxamers, or newer surfactant systems could be investigated, but substitution would require a full comparability package. A change in surfactant is unlikely to create a simple lifecycle-management opportunity unless it produces a measurable benefit in stability, particle reduction, or device compatibility.

What commercial opportunities exist for EVKEEZA excipients?

The strongest opportunities are incremental and supply-chain driven rather than based on a novel excipient claim.

1. Pharmaceutical-grade polysorbate 80 supply

EVKEEZA uses a high-value biologic formulation in which excipient quality directly affects product stability. Suppliers can compete through:

• Low-peroxide and low-particulate grades.
• Tighter control of hydrolytic impurities.
• Better documentation for global regulatory submissions.
• Dual-source qualification.
• Long-term supply agreements.
• Dedicated manufacturing campaigns for biologic customers.

A supplier with validated low-degradation polysorbate 80 could capture value even if the formulation remains unchanged. The opportunity is strongest where the sponsor seeks resilience against batch variability or plans additional presentations.

2. High-purity histidine and arginine systems

Histidine and L-arginine are commodity-like compared with the antibody, but biologic manufacturers still require consistent endotoxin, bioburden, trace-metal, and particulate performance. Specialty suppliers can differentiate through:

• Global pharmacopoeial compliance.
• Low-metal grades.
• Consistent pH and osmolality contribution.
• Documentation supporting biologic manufacturing.
• Reliable supply in the United States, Europe, and Asia.

The commercial value per dose is low, but recurring annual demand and multi-product supply agreements can make these materials attractive.

3. Excipient premixes

A validated liquid or solid premix containing histidine, arginine hydrochloride, and polysorbate 80 could reduce manufacturing complexity. Premixes may improve:

• Weighing and dispensing accuracy.
• Batch-record simplicity.
• Operator safety.
• Manufacturing cycle time.
• Raw-material testing burden.

The sponsor would still need to demonstrate control of concentration, homogeneity, bioburden, and stability. Premixes have greater value in contract manufacturing settings or in facilities producing several antibody products with similar buffer systems.

4. Vial and closure compatibility

The current product is supplied in single-dose vials. Container-closure components affect adsorption, extractables, particles, and protein stability. Commercial opportunities include:

• Low-binding glass or polymer containers.
• Improved elastomer stoppers.
• Low-particulate coatings.
• Better resistance to silicone-oil-related particles.
• Ready-to-use vial configurations.

For EVKEEZA, packaging improvements could reduce product loss during preparation and infusion. This matters because the drug is expensive and supplied at two fixed vial sizes.

What formulations are protected by EVKEEZA intellectual property?

Publicly available product information confirms the commercial formulation but does not establish that the marketed excipient combination is protected by an enforceable, formulation-specific patent. The relevant EVKEEZA patent estate is more likely to include several layers:

Patent category	Potential subject matter	Commercial impact
Antibody composition	Evinacumab sequences and binding characteristics	Core biosimilar barrier
ANGPTL3 inhibition	Use of the antibody for lipid disorders and HoFH	Method-of-use protection
Manufacturing	Cell culture, purification, and antibody production	Process and know-how barrier
Formulation	Concentration, pH, stabilizers, surfactants, and storage	Lifecycle-management protection
Administration	Dose, infusion schedule, and patient selection	Label and method-of-use protection
Combination therapy	Use with statins, ezetimibe, PCSK9 inhibitors, or other lipid therapies	Potential incremental protection

A formulation patent would have greater commercial value if it covered the marketed 150 mg/mL concentration, the histidine-arginine-polysorbate system, a defined stability profile, or a particular container-closure configuration. Broad claims to conventional excipients may face validity and obviousness challenges. Narrow claims tied to measured stability, aggregation control, or a specific manufacturing process may be more defensible.

The Purple Book, rather than the Orange Book, is the relevant FDA reference for biologic exclusivity and biosimilar information. EVKEEZA is not a small-molecule product listed in the Orange Book, and a generic applicant cannot file a conventional Paragraph IV certification against it. [2]

When does EVKEEZA lose exclusivity?

FDA approval occurred on February 11, 2021. Under the Biologics Price Competition and Innovation Act, a reference biological product generally receives 12 years of reference-product exclusivity from first licensure. On that basis, the statutory reference-product exclusivity period runs to approximately February 11, 2033. [2,3]

This date does not necessarily equal the first possible biosimilar launch date. A biosimilar sponsor may begin development before expiration and may file an application under section 351(k). Launch timing can depend on:

• Patent litigation under the biologics patent-dispute framework.
• Settlement agreements.
• Patent-term adjustments or extensions.
• Validity and infringement outcomes.
• Pediatric exclusivity, if applicable.
• Manufacturing and regulatory readiness.

The absence of an Orange Book listing means the classic small-molecule Paragraph IV timeline does not apply.

What biosimilar and generic entry risks exist for EVKEEZA?

EVKEEZA faces biosimilar rather than generic competition. The development barrier is substantial because evinacumab is a complex antibody requiring analytical, functional, and clinical comparability.

Main biosimilar barriers

A biosimilar developer would need to establish similarity across:

• Primary amino-acid sequence.
• Higher-order structure.
• Glycosylation and charge variants.
• Aggregates and fragments.
• Binding to ANGPTL3.
• Inhibition of ANGPTL3 function.
• Pharmacokinetic behavior.
• Immunogenicity.
• Manufacturing consistency.

The HoFH market is relatively small, which may limit the number of economically viable biosimilar programs. The commercial case improves if a developer can use the product in broader dyslipidemia populations or combine it with a lower-cost infusion infrastructure.

Likely entry scenarios

Scenario	Likely commercial effect
First biosimilar after exclusivity and patent resolution	Moderate price pressure, concentrated in large specialty centers
Multiple biosimilars	Greater discounting and payer leverage
Improved subcutaneous or lower-volume competitor	Potential shift away from infusion-based EVKEEZA
Formulation-only challenger	Limited value unless it enables a materially better presentation
Contract-manufactured biosimilar	Lower cost base but dependent on regulatory comparability

A biosimilar with the same IV route and four-week schedule would compete primarily on price, contracting, supply reliability, and site-of-care economics. A product that reduces infusion time or avoids infusion centers could compete on convenience and total treatment cost.

How can excipient strategy enable a differentiated EVKEEZA product?

High-concentration formulation

A higher-concentration formulation could reduce infusion volume and simplify administration. The current 150 mg/mL presentation is already concentrated for an antibody, so further concentration would require careful evaluation of viscosity, opalescence, aggregation, and injection-system compatibility.

Potential benefits include:

• Lower infusion volume.
• Smaller vial or fewer vials.
• Reduced preparation time.
• Better fit with outpatient infusion protocols.
• Potential compatibility with future wearable or autoinjector systems.

The main technical risks are increased viscosity, concentration-dependent aggregation, and greater sensitivity to interfacial stress.

Subcutaneous formulation

A subcutaneous version could expand administration options, particularly for patients receiving long-term treatment. The barriers are significant:

• The dose is weight-based and may be large.
• The required protein mass could exceed practical injection volumes.
• Hyaluronidase or other permeability technologies may be needed.
• Device compatibility would become central.
• Local tolerability would require evaluation.
• The excipient system might need to change substantially.

A subcutaneous formulation would be a high-value lifecycle opportunity because it could reduce infusion-center use. It also could create a distinct patent and regulatory package if supported by new concentration, device, excipient, and dosing claims.

Ready-to-use infusion presentation

A pharmacy-ready bag or pre-diluted presentation could reduce preparation errors and labor. It could be attractive for high-volume infusion centers, although HoFH treatment volume is limited relative to oncology and rheumatology biologics.

The formulation would need to demonstrate stability after dilution in commonly used infusion fluids and compatibility with administration sets. A validated in-use period could support centralized pharmacy preparation.

Lyophilized presentation

Lyophilization could improve stability and reduce dependence on liquid-state storage. Its commercial value is uncertain because EVKEEZA is already supplied as a ready-to-use solution. Lyophilization would add reconstitution steps, potentially increasing preparation time and dosing error. It would be most useful if liquid stability, global distribution, or supply-chain constraints became limiting.

What FDA regulatory issues affect EVKEEZA excipient changes?

Excipient changes in a licensed biologic would generally require a post-approval chemistry, manufacturing, and controls supplement. The regulatory burden depends on the change.

Lower-risk changes may include:

• A qualified alternate supplier for histidine or arginine.
• Tightened excipient specifications.
• Manufacturing-site changes with demonstrated comparability.

Higher-risk changes include:

• Replacing polysorbate 80.
• Changing excipient concentration.
• Moving from vial to prefilled device.
• Increasing antibody concentration.
• Changing container-closure materials.
• Introducing a subcutaneous route.
• Changing the infusion-dilution protocol.

The sponsor would need a comparability assessment covering critical quality attributes, stability, potency, impurities, particles, and immunogenicity risk. A new route or materially different dosage form could require clinical bridging rather than a purely analytical package. FDA guidance on post-approval changes for biological products and ICH Q5E comparability principles are central to the strategy. [4,5]

Which companies could benefit from EVKEEZA excipient demand?

Potential beneficiaries fall into four groups:

1. Pharmaceutical excipient producers supplying high-purity polysorbate 80, histidine, and arginine hydrochloride.
2. Container-closure and delivery-system companies supporting low-binding vials, stoppers, syringes, and infusion components.
3. Contract development and manufacturing organizations with antibody formulation and fill-finish capabilities.
4. Biosimilar developers able to reproduce or improve the current excipient system at lower cost.

The strongest commercial positioning will come from suppliers that provide validated biologic-grade materials, technical support, regulatory documentation, and dual-source continuity. Commodity pricing alone is unlikely to create a durable advantage.

What is the competitive landscape for ANGPTL3 and HoFH therapies?

EVKEEZA competes with established lipid-lowering therapies rather than only with future evinacumab biosimilars. HoFH treatment can include statins, ezetimibe, PCSK9-directed therapy where appropriate, lomitapide, LDL apheresis, and other specialist interventions.

Evinacumab has a distinct mechanism because its LDL-lowering effect does not depend on functional LDL receptors to the same extent as many conventional therapies. This supports its use in severe HoFH, but the small patient population and IV administration constrain market expansion.

A differentiated formulation could improve the product’s position against:

• Oral therapies with adherence limitations.
• Apheresis with high site-of-care burden.
• Other injectable biologics with more convenient administration.
• Future ANGPTL3-directed products.
• Biosimilars competing on price.

What patent litigation and settlement issues affect EVKEEZA?

There is no Paragraph IV litigation pathway for EVKEEZA because it is a biologic. Relevant disputes would more likely involve:

• Biosimilar patent litigation under the BPCIA.
• Antibody sequence or epitope claims.
• Method-of-use claims for HoFH.
• Formulation and concentration claims.
• Manufacturing-process claims.
• Device or container patents.

A settlement could establish a licensed biosimilar entry date before expiry of selected patents, subject to applicable legal and regulatory constraints. The commercial effect would depend on whether the settlement covers only the antibody or also formulation, manufacturing, and delivery technologies.

Key Takeaways

• EVKEEZA uses a conventional biologic excipient system based on histidine, L-arginine hydrochloride, polysorbate 80, and water for injection.
• The highest-value excipient opportunity is supply assurance and low-degradation polysorbate 80, not a commodity excipient price premium.
• The product is IV-only, weight-based, administered every four weeks, and supplied in two single-dose vial sizes.
• Vial waste, infusion time, and specialty-center administration create the clearest commercial rationale for formulation and presentation improvements.
• A higher-concentration or subcutaneous version could provide meaningful lifecycle differentiation but would require substantial formulation, device, and clinical work.
• EVKEEZA is governed by the Purple Book and the 351(k) biosimilar pathway, not the Orange Book and Paragraph IV process.
• FDA reference-product exclusivity is expected to extend to approximately February 2033, while patent and settlement outcomes may affect actual biosimilar launch timing.
• Conventional excipient claims are likely weaker than claims tied to concentration, stability, container compatibility, manufacturing, or a novel delivery system.
• The limited HoFH population may restrict the number of commercially viable biosimilar programs, increasing the value of manufacturing efficiency and site-of-care improvements.

FAQs

Can EVKEEZA be reformulated with polysorbate 20 instead of polysorbate 80?

Potentially, but the change would require extensive comparability testing. Polysorbate substitution can affect aggregation, particles, oxidation, container interaction, and long-term stability. It would be a higher-risk post-approval change.

Is EVKEEZA eligible for a conventional generic application?

No. EVKEEZA is a biologic, so competitors would generally pursue a biosimilar application under section 351(k) of the Public Health Service Act rather than an abbreviated new drug application.

Could a new excipient create a separate EVKEEZA patent estate?

Yes, if the excipient produces a patentable and non-obvious formulation with defined technical advantages. A generic buffer or surfactant substitution alone would face greater validity risk than a formulation tied to measurable stability, concentration, device compatibility, or reduced aggregation.

What is the most commercially attractive next-generation EVKEEZA presentation?

A lower-volume, higher-concentration presentation is the most direct near-term opportunity. A subcutaneous version could have greater commercial impact but would face higher dose-volume, device, tolerability, and clinical-development barriers.

Does EVKEEZA have an Orange Book listing?

No. As a biologic, EVKEEZA is tracked through the FDA Purple Book framework. Patent and biosimilar issues therefore follow the biologics regulatory pathway rather than the small-molecule Orange Book and Paragraph IV system.

References

1. U.S. Food and Drug Administration. (2024). EVKEEZA (evinacumab-dgnb) prescribing information. Regeneron Pharmaceuticals, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761181s005lbl.pdf

2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

3. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003.

4. U.S. Food and Drug Administration. (2017). Questions and answers on biosimilar development and the BPCI Act: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-biosimilar-development-and-bpci-act

5. International Council for Harmonisation. (2004). ICH Q5E: Comparability of biotechnological/biological products subject to changes in their manufacturing process. https://database.ich.org/sites/default/files/Q5E_Guideline.pdf